Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Extensive-stage small cell lung cancer (ES-SCLC) prognosis remains poor. The phase 3 RATIONALE-312 study aimed to evaluate efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for ES-SCLC.